TO: Regulatory Information Service
PR Newswire
RE: PARAGRAPH 3.1.4 OF THE DISCLOSURE AND TRANSPARENCY RULES
The notifications listed below were all received under Paragraph 3.1.2 of the
Disclosure and Transparency Rules.
Diageo plc (the "Company") announces that:
1. It received notification on 10 May 2013 of the following allocations of
ordinary shares of 28 101/108 pence each in the Company ("Ordinary Shares")
under the Diageo Share Incentive Plan (the "Plan"), namely:
(i) the following directors of the Company were allocated Ordinary Shares on 10
May 2013 under the Plan, by Diageo Share Ownership Trustees Limited (the
"Trustee"):
Name of Director Number of Ordinary Shares
D Mahlan 9
PS Walsh 9
(ii) the following Persons Discharging Managerial Responsibilities ("PDMR")
were allocated Ordinary Shares on 10 May 2013 under the Plan, by the Trustee:
Name of PDMR Number of Ordinary Shares
N Blazquez 9
D Gosnell 9
J Grover 9
A Morgan 9
S Moriarty 9
G Williams 9
I Wright 9
The number of Ordinary Shares allocated comprises those purchased on behalf of
the employee using an amount which the employee has chosen to have deducted
from salary ("Sharepurchase") and those awarded to the employee by the Company
("Sharematch") on the basis of one Sharematch Ordinary Share for every two
Sharepurchase Ordinary Shares.
The Sharepurchase Ordinary Shares were purchased and the Sharematch Ordinary
Shares were awarded at a price per share of £20.19.
The Ordinary Shares are held by the Trustee and in the name of the Trustee.
Sharepurchase Ordinary Shares can normally be sold at any time. Sharematch
Ordinary Shares cannot normally be disposed of for a period of three years
after the award date.
2. It received notification on 10 May 2013 that Dr FB Humer, a director of the
Company, had purchased 411 Ordinary Shares on 10 May 2013 under an
arrangement with the Company, whereby he has agreed to use an amount of £
8,000 each month, net of tax, from his director's fees to purchase Ordinary
Shares. Dr Humer has agreed to retain the Ordinary Shares while he remains
a director of the Company.
The Ordinary Shares were purchased at a price per share of £20.19.
3. It received notification on 10 May 2013 that Gareth Williams, a PDMR,
exercised options on 10 May 2013 over 89,914 Ordinary Shares granted under
the Company's Senior Executive Share Option Plan ("SESOP"). The options
were granted on 18 September 2007 at an exercise price of £10.51.
Of the shares arising, Mr Williams sold 88,500 Ordinary Shares at a price per
Ordinary Share of £20.19 and retained the balance of 1,414 Ordinary Shares.
As a result of the above transactions, interests of directors and PDMRs in the
Company's Ordinary Shares and American Depository Shares ("ADS")* (excluding
options, awards under the Company's LTIPs and interests as potential
beneficiaries of the Company's Employee Benefit Trusts) are as follows:
Name of Director Number of Ordinary Shares
Dr FB Humer 46,459
D Mahlan 132,324 (of which 131,691 are held as
ADS)
PS Walsh
769,641
Name of PDMR Number of Ordinary Shares
N Blazquez 72,434
D Gosnell 110,555
J Grover 187,021
A Morgan 142,985
S Moriarty 28,750
G Williams 179,680 (of which 6,535 are held as ADS)
I Wright 56,305
J Nicholls
Deputy Company Secretary
10 May 2013
*1 ADS is the equivalent of 4 Ordinary Shares.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.